TenecteRel® (Tenecteplase) - LifeSciences
- AbcixiRel® (Abciximab)
- AdaliRel® (Adalimumab)
- BevaciRel® (Bevacizumab)
- ChorioRel® (r-hCG)
- DarbeRel® (Darbepoetin)
- EtanerRel® (Etanercept)
- FostiRel® (FSH)
- Infimab® (Infliximab)
- MIRel® (Reteplase)
- Peg-ReliGrast® (Peg-GCSF)
- ReliBeta® (Interferon beta-1a)
- ReliFeron® (Interferon α)
- ReliGrast® (GCSF)
- ReliPoietin® (Erythropoietin)
- RituxiRel® (Rituximab)
- SomatoRel® (r-hGH)
- TenecteRel® (Tenecteplase)
- TrastuRel® (Trastuzumab)
TenecteRel (Tenecteplase) is the latest third generation tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese Hamster Ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle -1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.
Tenecteplase has advantages of single bolus administration, least time for administration, highest resistance to plasminogen activator inhibitor (PAI) and high fibrin specificity.
TenecteRel (Tenecteplase) is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.
TenecteRel (Tenecteplase) is the only fibrinolytic, which is recommended as half dose in patients > 75 years of age.
TenecteRel (Tenecteplase) is for intravenous administration only. The dose is weight-based and should not exceed 50 mg. A single bolus dose should be administered over five seconds based on patient weight.
TenecteRel (Tenecteplase) is available as 30, 40 and 50 mg kits. Each kit of TenecteRel® contains one Tenecteplase lyophilized vial (30/40/50 mg), sterile water for injection, one sterile disposable syringe, two needles and three alcohol swabs.